CAR T CELL THERAPY MARKET ANALYSIS

CAR T Cell Therapy Market, By Targeted Antigen (CD19, BCMA, HER2, GD2, CD20, CD22, CD30, CD33, HER1, Others (CLDN18, etc.)), By Therapeutic Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Glioblastoma, Sarcoma, Neuroblastoma, Acute Myeloid Leukemia, Breast Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Others (Gastric Cancer, etc.)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI102
Pages :222
Formats :
Excel and PDF
Industry : Biotechnology

Car T Cell Therapy MarketSize and Trends

Global CAR T cell therapy market is estimated to be valued at US$ 2.26 Billion in 2022 and is expected to exhibit a CAGR of 20.9 % during the forecast period (2022-2030).

Increasing prevalence of cancer is expected to propel growth of the global CAR T cell therapy market during the forecast period. For instance, in February 2022, the World Health Organization (WHO) published a fact sheet according to which, every year around 400,000 children develop cancer and 2.26 million cases of breast cancer were found in 2021, globally.

Furthermore, key companies focusing on product approval is expected to propel growth of the global CAR T cell therapy market during the forecast period. For instance, in April, 2022, Kite Pharma, Inc., a subsidiary of Gilead Sciences, Inc., one of the research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, obtained the U.S. Food and Drug Administration approval for Yescarta for initial treatment of relapsed or refractory large B-cell lymphoma (LBCL).